Navigation Links
Capital BlueCross and P4 Healthcare Launch Cancer Pathways Initiative
Date:1/13/2010

HARRISBURG, Pa., Jan. 13 /PRNewswire/ -- Capital BlueCross and P4 Healthcare announced today the launch of an innovative initiative to create clinically proven, evidence-based oncology treatment protocols aimed at enhancing the quality of care for patients.  The P4 Pathways Program will provide the tools to establish disease-specific and locally-based pathways for the treatment of patients with cancer, as well as protocols for supportive care (treatment of complications and adverse events that arise from the medical condition or administration of treatment).  The pathways are a collaborative effort that will be developed with oncologists across the entire Capital BlueCross network as a way to provide cost-effective care and improve the quality of health care delivery without comprising the integrity or delivery of treatment.

"We are constantly looking for ways to improve the care delivered to our members.  This program is compelling because it is driven by evidence-based pathways that include the guidance of local oncologists who understand the unique needs of those facing health challenges," said Capital BlueCross President & CEO Bill Lehr.

Capital BlueCross and P4 Healthcare have assembled a panel of local physicians to develop and maintain an up-to-date framework for the P4 Pathways Program based on clinical evidence to ensure best patient outcomes.  The P4 Pathways are designed to provide high-quality patient care and reward physicians for delivering appropriate care while managing costs.

"The P4 Pathways Program brings together the key stakeholders in the care of a patient.  The intent of this program is to ensure highest quality of cancer care for Capital BlueCross patients through the adoption of evidence-based clinical pathways," said Jeffrey Scott
'/>"/>

SOURCE Capital BlueCross
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. AtriCure to Present at Roth Capital Partners 2007 New York Conference
3. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
4. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
5. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
6. iCAD to Present at Americas Growth Capital 4th Annual Emerging Growth Conference
7. Pharsight Files Application for Nasdaq Capital Market Listing
8. Advanced Life Sciences Joins NASDAQ Capital Market
9. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
10. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
11. Caxton-Iseman Capital Acquires Conney Safety Products, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Atlanta, Georgia (PRWEB) May 04, 2015 Each ... the country to raise funds and awareness for breast cancer. ... Plastic Surgery will be featured as the entertainment sponsor for ... the Cure” on May 9 at the Lenox Square Mall. ... year’s Atlanta race, and to raise $1.2 million. Perimeter Plastic ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be ... Group (RUG) Conference in Baltimore, MD from May 11 ... Group provides an opportunity for clients to gather to ... , In addition to sponsoring the event, TROY Healthcare ... RUG Conference. Attendees can stop by the TROY booth ...
(Date:5/4/2015)... May 04, 2015 In May of 2010, ... his own life. In the wake of this tragedy, Ty’s ... an organization that exposes the grim reality of bullying and ... platform for Kirk and Laura to share their story and ... from happening to another family — a mission that took ...
(Date:5/4/2015)... 04, 2015 EY today announced that ... a finalist for the EY Entrepreneur Of The Year® ... awards program recognizes entrepreneurs who demonstrate excellence and extraordinary ... personal commitment to their businesses and communities. Mr. ... of independent judges. Award winners will be announced ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 New findings ... Brain Tumor Association (ABTA) show that people diagnosed with ... and treatment options, including clinical trials, at the time ... to make difficult decisions about their course of treatment. ... of the first nationwide brain tumor volunteer network, the ...
Breaking Medicine News(10 mins):Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
... center, which can go awry , , WEDNESDAY, Jan. 23 ... part of the brain handles what might be called ... lead scientists closer to more effective treatments for a ... brain region is helpful because it provides insight into ...
... fingertips to tap or press a surface is essential ... use a BlackBerry or an iPhone. But researchers ... seemingly trivial action is the result of a complex ... nervous system and muscles of the hand. , ...
... 23, 2008RNA interference (RNAi) represents an innovative new strategy ... associated with disease processes, and a series of review ... RNAi and microRNAs will begin with two review papers ... of Human Gene Therapy, a peer-reviewed journal published by ...
... increased by 18.0% to ... - Medical enrollment grew by 708,000 members during 2007, - Selling, general and ... by 120 basis points during the year, - Operating cash flow exceeded $4.3 billion for the year, or 1.3 ... income, - Company reiterates ...
... KIRKLAND, Wash., Jan. 23 "A failing mind, not ... today," says Cameron,Truesdell, CEO of LTC Financial Partners, the ... be, so we,re going to give,our clients information to ... offering a free guidebook and web links to helpful ...
... for Gestiva(TM) Anticipated in Calendar 2008, Gestiva(TM), is Designated ... Prevention ... in Singleton Pregnancies, ST. LOUIS, Jan. 22 ... company that,develops, manufactures, acquires and markets technology-differentiated,branded and generic/non-branded ...
Cached Medicine News:Health News:Specific Brain Region Governs Problem-Solving Skills 2Health News:Specific Brain Region Governs Problem-Solving Skills 3Health News:What gives us fingertip dexterity? 2Health News:What gives us fingertip dexterity? 3Health News:The RNA drug revolution -- a new approach to gene therapy 2Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 2Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 3Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 4Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 5Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 6Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 7Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 8Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 9Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 10Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 11Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 12Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 13Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 14Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 15Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 16Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 17Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 18Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 19Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 20Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 21Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 22Health News:WellPoint Reports Fourth Quarter and Full Year 2007 Results 23Health News:Long Term Care Insurance Leader Offers Advice on Preventing Dementia, the Leading Cause of Care Claims 2Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 2Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 3Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 4Health News:KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM) 5
(Date:5/4/2015)... Calif. , May 4, 2015 Rogne ... for psoriasis, today announced that preclinical and mechanism of ... at the Society of Investigative Dermatology (SID) Annual Meeting ... in Atlanta, Georgia . ... advancing the development of RON2315, a novel, low MW ...
(Date:5/4/2015)... WHIPPANY, N.J. , May 4, 2015 ... agreement with Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... clinical development for the prevention of thrombosis. Under the ... in areas of high unmet medical need. As ... evaluate the therapeutic profile of ISIS-FXI Rx in ...
(Date:5/4/2015)... BUFFALO, N.Y. , May 4, 2015 /PRNewswire/ ... Stephanie Englert , PharmD, has completed preliminary analysis ... Disorder and Schizophrenia. Resources from Clinical Support Services, ... Medication Reviews (CMR) with patients currently taking psychiatric ... events. The research found that 93% of patients ...
Breaking Medicine Technology:Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3
... 2, 2012 New Report Added in ... (General, Local, Adjunctive) The World Anesthesia ... , General Anesthesia Local Anesthesia ...   To Browse Full TOC, Tables & Figures visit: ...
... SAN DIEGO, May 2, 2012 Zogenix, Inc. (NASDAQ: ... developing products for the treatment of central nervous system ... submitted a New Drug Application (NDA) to the U.S. ... extended-release capsules), Zogenix,s lead investigational product candidate for the ...
Cached Medicine Technology:ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 2ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 3ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 4ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 5ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report 6Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 2Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 3Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 4Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 5Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain 6
30 cm - 11 3/4, packages 5 pcs....
23 cm - 9, adult size, for skull thickness up to 12 mm....
Length-9 (229 mm) Tapered retractor blades. 1/16 x 1/4 (1.6 mm x 19 mm)....
Length 6 (152 mm). Greenberg Retractor Kit is supplied with two primary bars. Primary bars attach to skull clamp....
Medicine Products: